Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates

Journal of Korean Medical Science

Volumn 28, Issue 1, 2013, Pages 62-66

  Chung, Hae Sun ^a   Hong, Seong Geun ^b   Kim, Young Ree ^c   Shin, Kyeong Seob ^d   Whang, Dong Hee ^e   Ahn, Jee Young ^f   Park, Yeon Joon ^g   Uh, Young ^h   Chang, Chulhun L ⁱ   Shin, Jong Hee ^j   Lee, Hye Soo ^k   Lee, Kyungwon ^a   Chong, Yunsop ^a  

^a Yonsei University College of Medicine   (South Korea)

^b CHA University   (South Korea)

^c Jeju National University School of Medicine   (South Korea)

^d Chungbuk National University College of Medicine   (South Korea)

^e Inje University College of Medicine   (South Korea)

^f Department of Laboratory Medicine   (South Korea)

^g The Catholic University of Korea College of Medicine   (South Korea)

^h Yonsei University Wonju College of Medicine   (South Korea)

ⁱ Pusan National University School of Medicine   (South Korea)

^j Chonnam National University Medical School   (South Korea)

^k Chonbuk National University Medical School   (South Korea)

more..

Author keywords

Combination drug therapy; Stenotrophomonas maltophilia; Ticarcillin clavulanate; Trimethoprim sulfamethoxazole

Indexed keywords

ANTIINFECTIVE AGENT; COTRIMOXAZOLE; MINOCYCLINE; OFLOXACIN;

ARTICLE; DRUG COMBINATION; DRUG EFFECT; GRAM NEGATIVE INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SOUTH KOREA; STENOTROPHOMONAS MALTOPHILIA; TICARCILLIN-CLAVULANATE; TRIMETHOPRIM-SULFAMETHOXAZOLE; UNIVERSITY HOSPITAL;

COMBINATION DRUG THERAPY; STENOTROPHOMONAS MALTOPHILIA; TICARCILLIN-CLAVULANATE; TRIMETHOPRIM-SULFAMETHOXAZOLE;

ANTI-INFECTIVE AGENTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; OFLOXACIN; REPUBLIC OF KOREA; STENOTROPHOMONAS MALTOPHILIA; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84874775082     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.1.62     Document Type: Article

References (34)

1. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 2012; 25: 2-41.
2. Abbott IJ, Slavin MA, Turnidge JD, Thursky KA, Worth LJ. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev Anti Infect Ther 2011; 9: 471-88.
3. Jang TN, Wang FD, Wang LS, Liu CY, Liu IM. Xanthomonas maltophilia bacteremia: an analysis of 32 cases. J Formos Med Assoc 1992; 91: 1170-6.
4. Victor MA, Arpi M, Bruun B, Jonsson V, Hansen MM. Xanthomonas maltophilia bacteremia in immunocompromised hematological patients. Scand J Infect Dis 1994; 26: 163-70.
5. Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob Agents Chemother 2000; 44: 287-93.
6. Alonso A, Martinez JL. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1997; 41: 1140-2.
7. Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis 2009; 9: 312-23.
8. Liaw SJ, Teng LJ, Hsueh PR, Ho SW, Luh KT. In vitro activities of antimicrobial combinations against clinical isolates of Stenotrophomonas maltophilia. J Formos Med Assoc 2002; 101: 495-501.
9. Muder RR, Harris AP, Muller S, Edmond M, Chow JW, Papadakis K, Wagener MW, Bodey GP, Steckelberg JM. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 1996; 22: 508-12.
10. Clinical Laboratory and Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-first Informational Supplement. Wayne, 2011.
11. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
12. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 2001; 32 Suppl 2: S104-13.
13. Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents 2005; 25: 95-109.
14. Fedler KA, Biedenbach DJ, Jones RN. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn Microbiol Infect Dis 2006; 56: 427-36.
15. Laing FP, Ramotar K, Read RR, Alfieri N, Kureishi A, Henderson EA, Louie TJ. Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment. J Clin Microbiol 1995; 33: 513-8.
16. Wang WS, Liu CP, Lee CM, Huang FY. Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J Microbiol Immunol Infect 2004; 37: 359-65.
17. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004; 48: 168-71.
18. Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2002; 46: 1105-7.
19. Betriu C, Sanchez A, Palau ML, Gomez M, Picazo JJ. Antibiotic resistance surveillance of Stenotrophomonas maltophilia, 1993-1999. J Antimicrob Chemother 2001; 48: 152-4.
20. Zhanel GG, DeCorby M, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagace-Wiens P, Walkty A, Mulvey MR, Hoban DJ. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn Microbiol Infect Dis 2008; 62: 67-80.
21. Valdezate S, Vindel A, Loza E, Baquero F, Canton R. Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains. Antimicrob Agents Chemother 2001; 45: 1581-4.
22. Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother 1994; 38: 624-7.
23. Nicodemo AC, Araujo MR, Ruiz AS, Gales AC. In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods. J Antimicrob Chemother 2004; 53: 604-8.
24. Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2000; 45: 363-5.
25. Travassos LH, Pinheiro MN, Coelho FS, Sampaio JL, Merquior VL, Marques EA. Phenotypic properties, drug susceptibility and genetic relatedness of Stenotrophomonas maltophilia clinical strains from seven hospitals in Rio de Janeiro, Brazil. J Appl Microbiol 2004; 96: 1143-50.
26. Wu H, Wang JT, Shiau YR, Wang HY, Yang Lauderdale TL, Chang SC. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J Microbiol Immunol Infect 2012; 45: 120-6.
27. Chung HS, Hong SG, Lee Y, Kim M, Yong D, Jeong SH, Lee K, Chong Y. Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from a Korean tertiary care hospital. Yonsei Med J 2012; 53: 439-41.
28. Belvisi V, Fabietti P, Del Borgo C, Marocco R, Di Vincenzo E, Soscia F, Mastroianni CM. Successful treatment of Stenotrophomonas maltophilia soft tissue infection with tigecycline: a case report. J Chemother 2009; 21: 367-8.
29. Blanquer D, De Otero J, Padilla E, Gomez F, Mayol A, Irigaray R, Espejo P, Rada MA, Makrantoni G, Perez AR. Tigecycline for treatment of nosocomial-acquired pneumonia possibly caused by multi-drug resistant strains of Stenotrophomonas maltophilia. J Chemother 2008; 20: 761-3.
30. Galles AC, Jones RN, Sader HS. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results? J Chemother 2008; 20: 38-42.
31. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother 2010; 54: 2735-7.
32. Chen YH, Lu PL, Huang CH, Liao CH, Lu CT, Chuang YC, Tsao SM, Chen YS, Liu YC, Chen WY. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010. Antimicrob Agents Chemother 2012; 56: 1452-7.
33. Poulos CD, Matsumura SO, Willey BM, Low DE, Mcgeer A. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother 1995; 39: 2220-3.
34. Gulmez D, Cakar A, Sener B, Karakaya J, Hascelik G. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J Infect Chemother 2010; 16: 322-8.